School of Medicine
Showing 2,451-2,460 of 12,891 Results
-
John W. Day, MD, PhD
Professor of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
On Partial Leave from 02/15/2026 To 10/18/2026Current Research and Scholarly InterestsOur Neuromuscular Division coordinates a comprehensive effort to conquer peripheral nerve and muscle disorders, including the muscular dystrophies, motor neuron disorders, neuromuscular junction abnormalities, and peripheral neuropathies. With patients and families foremost in mind, we have had success defining and combating these diseases, with research focused on identifying genetic causes, developing novel treatment, and maximizing patient function by optimizing current management.
-
John Robert Dayton
Clinical Assistant Professor, Emergency Medicine
BioBefore becoming an assistant professor, Dr. Dayton was the inaugural Medical Design and Innovation Fellow with Stanford's Department of Emergency Medicine. He also completed a Biodesign Faculty Fellowship with the Byers Center for Biodesign. In addition to practicing medicine, he co-founded the Stanford Emergency Medicine Partnership Program (STEPP), directed two Stanford Emergency Medicine Innovation Symposium (StEMIX) pitch events, and led the 2022 ACEP Hackathon.
Outside of Stanford, Dr. Dayton advises health-tech companies on strategy and physician user experience and works in VC. He co-founded Utah's Society of Physician Entrepreneurs and has served in both state and national leadership positions with the American College of Emergency Physicians (ACEP). He also works with Intermountain Health as an emergency physician and physician advisor to Intermountain Ventures and is a life science investor with Frame VC.
John's areas of expertise include digital therapeutics, healthcare innovation, AI operational tools, medical devices, clinical validation, academic-private pilot partnerships, and venture funding. -
Aglaia Kaissa de Boer
Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
BioKaïssa de Boer, MD is a board certified pulmonologist who specializes in the care of patients with interstitial lung disease. She completed her Internal Medicine and Pulmonary training at the University of Ottawa, Ottawa, Canada where her initial interest in caring for patients with fibrotic lung disease first developed. Subsequently she completed a fellowship in Interstitial Lung Disease at the University of California, San Francisco under the direction of Dr. Harold Collard. Dr. de Boer has a special interest in patients with connective tissue disease associated lung disease and those with drug induced pneumonitis. In addition she is actively involved in the ILD training and program development of Stanford's Pulmonary Allergy and Critical Care Fellows.
-
Walter De Brouwer
Adjunct Professor, Medicine - Primary Care and Population Health
BioWalter A. De Brouwer, Ph.D., is an Adjunct Professor at the Stanford School of Medicine. As a core faculty member at CERC DICE, he is the course director for “Innovation in Healthcare: from idea to incorporation,” which includes a bi-weekly presentation. He also serves on the advisory committee focused on the strategic direction for the program and is part of the leadership team developing the program curriculum and practicum. He is the founder of doc.ai, a Palo-Alto-based Federated Edge Learning company for the payers/pharma industry which merged in January 2020 with Sharecare Inc.
Professional Education
Bachelor’s degree in Philology (University of Ghent, Belgium)
Master’s degree in Formal Linguistics (University of Ghent, Belgium)
Post-graduate: Epistemology (University of Ghent, Belgium)
Ph.D. Computational Semiotics (Catholic University of Tilburg, the Netherlands). -
Korina De Bruyne
Clinical Assistant Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly InterestsThe EMPOWER study (PI: Dr Beth Darnall) is looking at how to best support patients with chronic pain on long-term opioid therapy through a slow taper (maximal duration of 1 year). Patients are randomized to taper only versus taper plus community-based pain self-management group sessions versus taper plus psychologist-led cognitive behavioral therapy for pain group sessions. Along the way alternative measures to control pain are also explored. Enrollment is open until 10/2021.
